With over 35 nationalities and a range of backgrounds represented in our Benevolent team, we aim to build an inclusive environment where our people can bring their authentic selves to work, be respected for who they are and the exceptional work they do. We welcome and actively encourage applications from all sections of society and are committed to offering equal employment opportunities regardless of sex, race, religion or belief, ethnic or national origin, marital, domestic or civil partnership status, sexual orientation, gender identity, parental status, disability, age, citizenship, or any other basis. We see our diversity as an asset as we tackle challenging problems that bridge the gap between drug discovery and technology.
As a DevOps Engineer, you will be working alongside our autonomous cross-functional squads. You will advocate high-quality engineering and best-practice in production software as well as provide the infrastructure to both build rapid prototypes and launch production-quality services. You must be a strong communicator who can explain what is required to build and deliver top quality software products. You will be keen to work with the rest of the team and develop collaboratively.
You will promote test-driven-development and other Agile best practices for ensuring the software is resilient enough for our scientists to rely upon. You will be a core team member building and maintaining the underlying infrastructure that supports our AI-driven technology. You will also be adding your input into diverse areas such as authentication, network topology, sharded databases, scalable web services and interfaces to external data sources and APIs.
We share a passion for being part of a mission that matters, and we are always looking for curious and collaborative people who share our values and want to be part of our journey. If that sounds like a fit for you, hit the apply button and join us.
BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
Our team will only contact you from the domain @benevolent.ai. If you receive a suspicious contact request, please email firstname.lastname@example.org. Thank you.